Purpose Of Review: Community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) is an emerging problem in pediatrics, with clinical and microbiologic characteristics that differentiate it from hospital-acquired MRSA (HA-MRSA).
Recent Findings: Relative to HA-MRSA, CA-MRSA tends to cause localized disease (although serious illness occurs), is susceptible to more antibiotics, and has the same risk factors for acquisition/disease as methicillin-susceptible S. aureus (MSSA). At the gene level, CA-MRSA is more similar to MSSA than HA-MRSA: its emergence is apparently due to acquisition by an MSSA of the Staphylococcal Cassette Chromosome that bears mecA: the gene that encodes the methicillin-resistant penicillin binding protein. Carriage of recognized staphylococcal virulence factors, particularly Panton-Valentine leukocidin, is common in CA-MRSA, emphasizing its potential for causing serious illness. CA-MRSA is usually susceptible to clindamycin, trimethoprim-sulfamethoxazole, and rifampin, but inducible macrolide-lincosamide-streptogramin resistance in a subset of CA-MRSA could be problematic when clindamycin is used.
Summary: The appearance and spread of CA-MRSA represents a new challenge in pediatric medicine. A high level of clinical suspicion and development of rapid methods for its identification are needs for the future.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.mop.0000147906.30720.4d | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
New Perspectives on Antimicrobial Agents: Omadacycline for community-acquired pneumonia, skin and soft tissue infections, and nontuberculous mycobacteria (focus on ).
Antimicrob Agents Chemother
January 2025
Norton Infectious Diseases Institute, Norton Healthcare, Louisville, Kentucky, USA.
Omadacycline is a novel antimicrobial belonging to the tetracycline class. It has the ability to evade both efflux and ribosomal methylation types of resistance and therefore has an expanded spectrum compared to other tetracycline agents. Omadacycline is active against a number of multidrug-resistant bacteria, including macrolide and doxycycline-resistant methicillin-resistant (MRSA), vancomycin-resistant Enterococcus, and several enteric gram-negative bacilli.
View Article and Find Full Text PDFCeftobiprole activity against multidrug-resistant clinical isolates collected in the United States from 2016 through 2022.
Antimicrob Agents Chemother
January 2025
JMI Laboratories, Element Materials Technology, North Liberty, Iowa, USA.
Ceftobiprole was recently approved by the United States (US) Food and Drug Administration (FDA) for the treatment of adult patients with bacteremia, including right-side endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia in adults and pediatrics. Ceftobiprole is an advanced-generation cephalosporin approved in many countries for the treatment of adults with community-acquired pneumonia and hospital-acquired pneumonia, excluding ventilator-associated pneumonia. We evaluated the activities of ceftobiprole and comparators against methicillin-resistant (MRSA) and multidrug-resistant (MDR) clinical isolates.
View Article and Find Full Text PDFEarly-Stage IM Treatment with the Host-Derived Immunostimulant CPDI-02 Increases Curative Protection of Healthy Outbred Mice Against Subcutaneous Infection with Community-Acquired Methicillin-Resistant USA300.
Pharmaceutics
December 2024
Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198, USA.
: Community-acquired methicillin-resistant (CA-MRSA) greatly complicates the treatment of skin and soft tissue infections (SSTI). It was previously found that subcutaneous (SQ) treatment with the mononuclear phagocyte (MP)-selective activator complements peptide-derived immunostimulant-02 (CPDI-02; formerly EP67) and increases prophylaxis of outbred CD-1 mice against SQ infection with CA-MRSA. Here, we determined if treatment with CPDI-02 also increases curative protection.
View Article and Find Full Text PDFIncreased Antibiotic Susceptibility of Gram-Positive Bacteria in Cerebrospinal Fluid Compared to Broth.
Antibiotics (Basel)
December 2024
Department of Geriatrics, Evangelisches Krankenhaus Göttingen-Weende, 37075 Göttingen, Germany.
In hospital- and community-acquired central nervous system infections, resistant Gram-positive bacteria are an increasing therapeutic challenge. The present approach does not attempt to identify rapidly bactericidal therapies for susceptible pathogens but aims to improve methods to find antibiotic regimens for multi-resistant pathogens that are effective in vivo in spite of reduced in vitro susceptibility in culture media. Antibiotic susceptibility was tested in cerebrospinal fluid (CSF) and Mueller-Hinton broth (, methicillin-resistant , ) or brain-heart infusion ().
View Article and Find Full Text PDFEvaluation of a Pharmacist-Led Methicillin-Resistant Nasal PCR Testing Protocol.
Antibiotics (Basel)
December 2024
Department of Pharmacy Practice, Auburn University Harrison College of Pharmacy, Auburn, AL 36849, USA.
Methicillin-resistant (MRSA) can cause cases of community-acquired pneumonia, hospital-acquired pneumonia, and ventilator-associated pneumonia, and nasal colonization with this pathogen increases the risk of infection. Due to its high negative predictive value, multiple studies support using the MRSA nasal polymerase chain reaction (PCR) test to discontinue antimicrobials that target MRSA in the setting of a negative test result. The purpose of this project was to assess the utility of a protocol to allow pharmacists the ability to order MRSA nasal PCR screenings in hospitalized patients with pneumonia.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!